Brochure
7 Sep 2026

GlycoNex: Anti-Glycan ADC & Biosimilar Partnering

PDF 1.2 MB
Download

Clinical-stage anti-glycan ADC GNX1021 (Ph1) and registration-ready denosumab biosimilar SPD8. Seeking licensing and co-development partners.

Content provided by our supplier

Taiwan Pharma Pavilion

  • Country/Region:
    Taiwan
  • On CPHI since:
    2025
  • Certificates:
    2
  • Employees:
    1000 - 4999
Company types
Association/Government
Biopharmaceutical company
CMO/CDMO
Contract Research Organisation (CRO)
Drug delivery device Supplier/Manufacturer
Generics/Biosimilars Manufacturer
IT/Software solution provider
Manufacturer/Innovator
Pharmaceutical company
Primary activities
API Producer
Biopharmaceutical
Chemical Development
Contract Manufacturer
Contract Research Organisation
Generic APIs producer
Pharmaceutical Company (generic finished products)
Pharmaceutical Company (innovator finished products)
View company profile

Other Content from Taiwan Pharma Pavilion (1)